bronchiectasis

From Aaushi
Jump to navigation Jump to search

Introduction

Chronic dilation of bronchi or bronchioles as a sequel of inflammatory disease or obstruction.

Etiology

Epidemiology

Pathology

  • most commonly occurs in lower lung fields
  • in most cases 2nd to 4th order bronchi are involved
  • bilateral involvement in 30%
  • ~20% of patients with bronchiectasis have eosinophilic inflammation[20]

Clinical manifestations

Laboratory

* eosinophil count < 100/uL associated with greater disease severity & mortality[20]

* higher eosinophilic counts were associated with shorter time to exacerbations[20]

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

More general terms

More specific terms

Additional terms

References

  1. Stedman's Medical Dictionary 26th ed, Williams & Wilkins, Baltimore, 1995
  2. Guide to Physical Examination & History Taking, 4th edition, Bates B, JB Lippincott, Philadelphia, 1987
  3. DeGowin & DeGowin's Diagnostic Examination, 6th edition, RL DeGowin (ed), McGraw Hill, NY 1994, pg 870
  4. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 746-48
  5. 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2015, 2018, 2022.
    Medical Knowledge Self Assessment Program (MKSAP) 20 American College of Physicians, Philadelphia 2025
  6. 6.0 6.1 Altenburg J et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 2013 Mar 27; 309:1251 PMID: https://pubmed.ncbi.nlm.nih.gov/23532241
    Serisier DJ et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013 Mar 27; 309:1260 PMID: https://pubmed.ncbi.nlm.nih.gov/23532242
  7. Chalmers JD, Smith MP, McHugh BJ et al Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. PMID: https://pubmed.ncbi.nlm.nih.gov/22744718
  8. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56 PMID: https://pubmed.ncbi.nlm.nih.gov/23898922
  9. Pasteur MC, Bilton D, Hill AT et al British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65 Suppl 1:i1-58. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/20627931
  10. 10.0 10.1 10.2 10.3 10.4 10.5 Aksamit TR et al. Adult patients with bronchiectasis: A first look at the US Bronchiectasis Research Registry. Chest 2017 May; 151:982 PMID: https://pubmed.ncbi.nlm.nih.gov/27889361
  11. 11.0 11.1 11.2 11.3 Anello J, Feinberg B, Heinegg J et. al. New Guidelines and Recommendations, October 2017 Medscape. Oct 06, 2017. http://reference.medscape.com/viewarticle/886616_15
  12. 12.0 12.1 12.2 NEJM JWatch Question of the Week. March 27, 2018 https://knowledgeplus.nejm.org/question-of-week/562/
  13. 13.0 13.1 Ebihara T, Sasaki H. Bronchiectasis with Mycobacterium avium Complex Infection. N Engl J Med 2002; 346:1372 <PubMed> PMID: https://pubmed.ncbi.nlm.nih.gov/11986411 Free full text <Internet> http://www.nejm.org/doi/full/10.1056/NEJMicm010899
  14. 14.0 14.1 NEJM Knowledge+ Question of the Week. June 19, 2018 https://knowledgeplus.nejm.org/question-of-week/1699/
  15. Milliron B, Henry TS, Veeraraghavan S, Little BP. Bronchiectasis: Mechanisms and Imaging Clues of Associated Common and Uncommon Diseases. Radiographics. 2015 Jul-Aug;35(4):1011-30. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/26024063
  16. Smith MP. Diagnosis and management of bronchiectasis. CMAJ. 2017 Jun 19;189(24):E828-E835. Review. PMID: https://pubmed.ncbi.nlm.nih.gov/28630359 Free PMC Article
  17. NEJM Knowledge+ Question of the Week. April 16, 2019 https://knowledgeplus.nejm.org/question-of-week/561/
  18. Barker AF. Bronchiectasis. N Engl J Med 2002 May 3; 346:1383. PMID: https://pubmed.ncbi.nlm.nih.gov/11986413 https://www.nejm.org/doi/full/10.1056/NEJMra012519
  19. Feldman C. Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med. 2011 Sep;32(3):535-46. Review. PMID:21867821
  20. 20.0 20.1 20.2 20.3 Shoemark A et al. Characterization of eosinophilic bronchiectasis: A European multicohort study. Am J Respir Crit Care Med 2022 Apr 15; 205:894. PMID: https://pubmed.ncbi.nlm.nih.gov/35050830 https://www.atsjournals.org/doi/10.1164/rccm.202108-1889OC
    Singh D, Brightling C. Bronchiectasis, the latest eosinophilic airway disease: What about the microbiome? Am J Respir Crit Care Med 2022 Apr 15; 205:860. PMID: https://pubmed.ncbi.nlm.nih.gov/35213295 https://www.atsjournals.org/doi/10.1164/rccm.202201-0105ED
  21. NEJM Knowledge+ Question of the Week. Nov 8, 2022 https://knowledgeplus.nejm.org/question-of-week/233/
    Thompson GR, Young JAH. Aspergillus infections. PMID: https://pubmed.ncbi.nlm.nih.gov/34644473 N Engl J Med 2021; 385:1496-1509 https://www.nejm.org/doi/full/10.1056/NEJMra2027424
    Patel G, Greenberger PA. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc 2019 Nov 1; 40:421-424. PMID: https://pubmed.ncbi.nlm.nih.gov/31690385
    Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. Allergy Asthma Immunol Res 2016 Jul; 8:282-97. PMID: https://pubmed.ncbi.nlm.nih.gov/27126721 PMCID: PMC4853505 Free PMC article
  22. O'Donnell AE. Bronchiectasis. Chest. 2008 Oct;134(4):815-823. PMID: https://pubmed.ncbi.nlm.nih.gov/18842914 Review.
  23. 23.0 23.1 NEJM Knowledge+
  24. 24.0 24.1 Guo R et al. Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis. Eur Respir J 2025 Mar; 65:2401574 PMID: https://pubmed.ncbi.nlm.nih.gov/39603670 PMCID: PMC11883147 https://publications.ersnet.org/content/erj/65/3/2401574
  25. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018;5:e000348. PMID: https://pubmed.ncbi.nlm.nih.gov/30687502
  26. 26.0 26.1 Chalmers JD et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 2025 Apr 24; 392:1569 PMID: https://pubmed.ncbi.nlm.nih.gov/40267423 https://www.nejm.org/doi/10.1056/NEJMoa2411664
    Bell SC, Grimwood K. Brensocatib in bronchiectasis - A new sheriff in town? N Engl J Med 2025 Apr 24; 392:1647. PMID: https://pubmed.ncbi.nlm.nih.gov/40267431 https://www.nejm.org/doi/10.1056/NEJMe2502618
  27. Aliberti S, Goeminne PC, O'Donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022;10:298-306. PMID: https://pubmed.ncbi.nlm.nih.gov/34570994
  28. 28.0 28.1 Pollock J et al. Use of inhaled corticosteroids in bronchiectasis: Data from the European Bronchiectasis Registry (EMBARC). Thorax 2025 Jun; 80:358. PMID: https://pubmed.ncbi.nlm.nih.gov/40122611 PMCID: PMC12128780 https://pmc.ncbi.nlm.nih.gov/articles/PMC12128780/
  29. 29.0 29.1 Bradley JM et al. Hypertonic saline or carbocisteine in bronchiectasis. N Engl J Med 2025 Oct 23; 393:1565. PMID: https://pubmed.ncbi.nlm.nih.gov/41020514 https://www.nejm.org/doi/10.1056/NEJMoa2510095
    Hansen-Flaschen J, Tino G. Time to reconsider mucoactive agents for airway clearance. N Engl J Med 2025 Oct 23; 393:1646. PMID: https://pubmed.ncbi.nlm.nih.gov/41020522 https://www.nejm.org/doi/10.1056/NEJMe2512146